& Hall, M
Our data indicate an increased risk of vomiting and nausea side effects associated with the Gln allele in tirzepatide-treated patients, which may result from a diminished ability of the GIP component of the drug to buffer the nausea-inducing effects of the GLP1 component
2024 DOI: 10.1038/s41421-024-00702-y PMID: 39019866 Read on PubMed European Journal of Clinical Pharmacology A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Kaur M, Misra S 2024 DOI: 10.1007/s00228-024-03646-0 PMID: 38367045 Read on PubMed Cardiology in Review The First Triple Agonist for Antiobesity: Retatrutide Tetelbaum L, Mullally JA, Frishman WH 2024 DOI: 10.1097/CRD.0000000000000793 PMID: 39724554 Read on PubMed NPJ Metabolic Health and Disease Incretin triple agonist retatrutide alleviates obesity-associated cancer progression Marathe SJ, Grey EW, Bohm MS, et al
Nausea, when it occurs, tends to be most intense during weeks 13-14 and resolves significantly by week 15-16
Without insulin, glucose (from the food we eat) doesnt get into our cells to be used for critical functions
Protect from excessive heat
